A list of chemotherapeutic nucleosidic analogs in clinical trials.
| Name | Structure | Statusa | Chemical modification | Targeted cancer | Mechanism of action | |
|---|---|---|---|---|---|---|
| Tezacitabine |
|
Phase I/II trials | • Sugar ring modification by fluoro-methylene-halogenation | • Refractory solid tumors | • Enzymatic inhibition | 43 |
| Troxacitabine |
|
Phase I/II trials | • Sugar ring modification by dihydroxylation | • Acute myelogenous leukemia (AML) | • Inhibitor of DNA polymerases | 44 and 45 |
| • l-Enantiomer | ||||||
| rx-3117 |
|
Phase I/II trials | • Sugar replacement by a cyclopentene ring and F-halogenation | • Metastatic bladder cancer | • DNA hypomethylation | 46 and 47 |
| • Metastatic pancreatic cancer | ||||||
| 8-Chloroadenosine |
|
Phase I/II trials | • Adenine modification by Cl-halogenation | • Recurrent acute myeloid leukemia | • Enzymatic inhibition | 48 |
a
Trial status was verified by the NIH – U.S. National Library of Medicine clinical trials database (http://www.clinicaltrials.gov).